PRKACB

cAMP-dependent protein kinase catalytic subunit beta · P22694 · PRKACB on Sugi Atlas →

27,675 patent compounds predicted against PRKACB, 19,695 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Gf-109203 (SCHEMBL338086)	1.00	13/20
Balanol (SCHEMBL62128)	1.00	10/20
Balanol (SCHEMBL62129)	1.00	10/20
Ucn-01 (SCHEMBL259162)	1.00	8/20
SCHEMBL224940	0.56	7/20
Staurosporine (SCHEMBL8156)	1.00	6/20
Staurosporine (SCHEMBL8157)	1.00	6/20
Staurosporine (SCHEMBL624944)	0.93	6/20
SCHEMBL190590	1.00	5/20
SCHEMBL566377	0.71	5/20
Hydrochloric Acid (SCHEMBL574657)	0.70	5/20
SCHEMBL567383	0.69	5/20
Hydrochloric Acid (SCHEMBL566393)	0.68	5/20
SCHEMBL566378	0.66	5/20
SCHEMBL566379	0.66	5/20
Hydrochloric Acid (SCHEMBL567555)	0.65	5/20
Hydrochloric Acid (SCHEMBL567556)	0.65	5/20
Hydrochloric Acid (SCHEMBL568137)	0.65	5/20
SCHEMBL566374	0.64	5/20
SCHEMBL566375	0.64	5/20

Clinical trials — most relevant to PRKACB by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Comparison of the Postoperative Use of Dextenza vs a Standard Regimen After PRK	PHASE4	UNKNOWN
Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds	PHASE2/PHASE3	COMPLETED
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	ACTIVE_NOT_RECRUITING
PKC412 and 5-Azacytidine	PHASE1/PHASE2	COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer	PHASE2	COMPLETED
Immunomodulating Therapy and Improved Vaccination Responses by Cox-2 Inhibitor in HIV-infected Patients	PHASE2	COMPLETED
A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)	PHASE2	COMPLETED
Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study	PHASE2	COMPLETED
Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer	PHASE2	COMPLETED
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma	PHASE2	COMPLETED
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia	PHASE1/PHASE2	COMPLETED
Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study	PHASE2	UNKNOWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Metformin's Effect on Glucagon-induced Glucose Production and Protein Metabolism.	PHASE1	COMPLETED
Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	EARLY_PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex	nan	COMPLETED
Exome Evaluation in Patients Living With Diabetes Complicated by Charcot Neuroarthropathy.	nan	COMPLETED
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.	nan	COMPLETED
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia	nan	UNKNOWN
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo	nan	UNKNOWN
Immune Signature of Palmoplantar Pustulosis	nan	COMPLETED
The Relation of Microtubule-Associated Protein 2 and Cell Migration	nan	UNKNOWN
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies	nan	ENROLLING_BY_INVITATION
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction	nan	COMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus	nan	UNKNOWN
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients	nan	COMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PRKACB binder may also engage these)

Protein	Name	Similarity
P05383	—	1.000	P05383 →
P05131	—	1.000	P05131 →
P68182	—	1.000	P68182 →
P68181	—	1.000	P68181 →
PRKACA	cAMP-dependent protein kinase catalytic subunit alpha	1.000	landscape →
Q8MJ44	—	1.000	Q8MJ44 →
P05132	—	0.999	P05132 →
P27791	—	0.998	P27791 →
P00517	—	0.998	P00517 →
P12370	—	0.998	P12370 →
Q9MZD9	—	0.997	Q9MZD9 →
P36887	—	0.996	P36887 →
P25321	—	0.996	P25321 →
P68180	—	0.994	P68180 →
A8XW88	—	0.992	A8XW88 →
PRKACG	cAMP-dependent protein kinase catalytic subunit gamma	0.991	landscape →
O62846	—	0.968	O62846 →
Q922R0	—	0.968	Q922R0 →
PRKX	cAMP-dependent protein kinase catalytic subunit PRKX	0.965	landscape →
P21137	—	0.964	P21137 →
Q7ZX15	—	0.956	Q7ZX15 →
P54644	—	0.956	P54644 →
Q9WUA6	—	0.956	Q9WUA6 →
P47197	—	0.953	P47197 →
PRKCB	Protein kinase C beta type	0.953	landscape →
P49673	—	0.952	P49673 →
Q5I6M2	—	0.952	Q5I6M2 →
Q63484	—	0.951	Q63484 →
PRKCA	Protein kinase C alpha type	0.951	landscape →
Q965G5	—	0.950	Q965G5 →